What is Omeros Corporation's earnings per share (EPS)?

Omeros Corporation (OMER) reported diluted earnings per share of -$0.05 for fiscal year 2025. This represents a 98.1% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Omeros Corporation (OMER) Financials

OMER

Trailing 12 months to June 30, 2026

Revenue Not reported for the trailing 12 months

EPS (Diluted) $1.72 +181.1% YoY

Free Cash Flow -$68.7M +42.2% YoY

Operating Cash Flow -$68.7M +42.2% YoY

Market Cap $1.3B as of Oct 3, 2026

Price / Sales n/m no revenue reported

Price / Earnings n/m no net income reported

Price / Book n/m negative shareholder equity, so no book multiple, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 3, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 12, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 12, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the OMER SEC filings page.

This page shows Omeros Corporation (OMER) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI OMER FY2025 2026-10-03

Omeros is funding a shrinking operating expense base with external financing and asset sales while cumulative losses keep equity negative.

Cash conversion is not the central problem: in FY2025, operating cash flow of -$116M nearly matched free cash flow of -$116M because capital spending was only $65K. That means the cash requirement comes mainly from ongoing operations, not from heavy reinvestment in physical assets.

Operating losses narrowed from -$174M in FY2021 to -$123M in FY2025 as research and development fell from $119M to $81M and selling, general, and administrative spending declined to $42M. With revenue not reported, the improvement is best read as cost reduction, not evidence of sales-driven operating leverage.

The balance sheet remains structurally strained: FY2025 liabilities of $447M exceeded assets of $326M, leaving equity at -$121M, even after long-term debt fell to $88M from $213M in FY2023. The current ratio of 2.8x and reported liquidity equivalent to 17.8 months of annual operating outflow indicate short-term resources are more favorable than the negative-equity capital structure.

Financial Health Signals

Financial health score not available

Omeros Corporation does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Interest Coverage At Risk

N/A

Omeros Corporation reported an operating loss of $122.8M against $960K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$28.5M

QoQ+188.4%

Omeros Corporation generated $28.5M in revenue in Q2 2026. Against the prior quarter it is up 188.4%.

EBITDA

$416K

YoY+101.3%

QoQ+102.4%

Omeros Corporation's EBITDA was $416K in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 101.3% from the same quarter a year earlier. Against the prior quarter it is up 102.4%.

Net Income

$13.2M

YoY+152.0%

QoQ-76.4%

Omeros Corporation reported $13.2M in net income in Q2 2026. This represents an increase of 152.0% from the same quarter a year earlier. Against the prior quarter it is down 76.4%.

EPS (Diluted)

$0.15

YoY+134.9%

QoQ-75.8%

Omeros Corporation earned $0.15 per diluted share (EPS) in Q2 2026. This represents an increase of 134.9% from the same quarter a year earlier. Against the prior quarter it is down 75.8%.

Cash & Balance Sheet

Free Cash Flow

$4.1M

YoY+118.7%

QoQ+128.3%

Omeros Corporation generated $4.1M in free cash flow in Q2 2026, representing cash available after capex. This represents an increase of 118.7% from the same quarter a year earlier. Against the prior quarter it is up 128.3%.

Cash & Debt

$2.0M

YoY+4.4%

QoQ+4.3%

5Y CAGR-31.0%

10Y CAGR-8.0%

Omeros Corporation held $2.0M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

72M

YoY+6.4%

QoQ0.0%

5Y CAGR+3.0%

10Y CAGR+6.3%

Omeros Corporation had 72M shares outstanding in Q2 2026. This represents an increase of 6.4% from the same quarter a year earlier. It is unchanged from the prior quarter.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

97.2%

QoQ+3.1pp

Omeros Corporation's gross margin was 97.2% in Q2 2026, indicating the percentage of revenue retained after direct costs. Against the prior quarter it is up 3.1 percentage points.

Operating Margin

0.3%

Omeros Corporation's operating margin was 0.3% in Q2 2026, reflecting core business profitability.

Net Margin

46.4%

Omeros Corporation's net profit margin was 46.4% in Q2 2026, showing the share of revenue converted to profit.

Return on Equity

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$13.8M

YoY-37.3%

QoQ+3.3%

Omeros Corporation invested $13.8M in research and development in Q2 2026. This represents a decrease of 37.3% from the same quarter a year earlier. Against the prior quarter it is up 3.3%.

Share Buybacks

$5.7M

QoQ+37.9%

Omeros Corporation spent $5.7M on share buybacks in Q2 2026, returning capital to shareholders by reducing shares outstanding. Against the prior quarter it is up 37.9%.

Capital Expenditures

$45K

YoY+246.2%

Omeros Corporation invested $45K in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 246.2% from the same quarter a year earlier.

OMER Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

OMER quarterly income statement

Metric	TTM	FY2510-Q	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	$73.8M-34.0%	$111.8M+274.3%	$29.9M-53.9%	$64.8M+55.8%	$41.6M+208.1%	$13.5M+2406.3%	$539K-66.3%	$1.6M-73.4%	$6.0M+33.1%	$4.5M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	$902K+4.3%	$865K+68.9%	$512K-52.5%	$1.1M-23.7%	$1.4M+35.6%	$1.0M	$0	$0	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	$72.9M-34.3%	$110.9M+277.9%	$29.4M-53.9%	$63.7M+58.6%	$40.2M+222.5%	$12.5M+2213.2%	$539K-66.3%	$1.6M	N/A	N/A
R&D Expenses	N/A	$81.3M-32.0%	$119.5M+4.1%	$114.9M+1.9%	$112.7M-5.1%	$118.8M+10.4%	$107.6M+1.2%	$106.3M+18.3%	$89.9M+61.6%	$55.6M+9.7%	$50.7M+4.8%	$48.4M+0.9%	$47.9M+32.1%	$36.3M+13.7%	$31.9M+34.6%	$23.7M
SG&A Expenses	N/A	$41.5M-12.5%	$47.4M-4.5%	$49.7M-2.0%	$50.7M-7.6%	$54.8M+11.2%	$49.3M+24.2%	$39.7M-23.2%	$51.7M-0.6%	$52.0M+18.9%	$43.8M+23.9%	$35.3M+56.3%	$22.6M+42.9%	$15.8M+44.0%	$11.0M+33.7%	$8.2M
Operating Income	N/A	-$122.8M+26.4%	-$167.0M-1.5%	-$164.5M-0.7%	-$163.4M+5.9%	-$173.6M-10.6%	-$156.9M-7.5%	-$146.0M-30.1%	-$112.2M-155.7%	-$43.9M+19.1%	-$54.3M+23.8%	-$71.2M	N/A	-$50.5M-37.0%	-$36.9M-34.6%	-$27.4M
EBITDA	N/A	-$121.8M+26.6%	-$166.0M-1.5%	-$163.6M-0.7%	-$162.4M+5.7%	-$172.2M-10.9%	-$155.3M-7.7%	-$144.2M-29.6%	-$111.3M-156.7%	-$43.3M+19.7%	-$54.0M+24.0%	-$71.0M	N/A	-$50.2M-37.3%	-$36.6M-35.6%	-$27.0M
Interest Expense	N/A	-$960K-103.9%	$24.7M-20.0%	$30.8M+35.9%	$22.7M+15.4%	$19.7M-26.5%	$26.8M+18.1%	$22.7M+39.4%	$16.3M+47.3%	$11.0M+41.1%	$7.8M+118.8%	$3.6M+3.0%	$3.5M+46.7%	$2.4M+36.8%	$1.7M-8.2%	$1.9M
Income Tax	N/A	$2.0M-12.7%	$2.3M	$0	$0	$0+100.0%	-$23.3M-17.6%	-$19.8M-52.9%	-$12.9M	$0	$0	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	N/A	N/A	N/A	$47.4M-75.6%	$194.2M+240.7%	-$138.1M-63.4%	-$84.5M+33.3%	-$126.8M-137.0%	-$53.5M+19.9%	-$66.7M+11.1%	-$75.1M	N/A	-$39.8M-3.5%	-$38.4M-34.7%	-$28.5M
EPS (Basic)	N/A	-$0.05+98.1%	-$2.70-43.6%	-$1.88-347.4%	$0.76-75.6%	$3.12+229.5%	-$2.41-40.9%	-$1.71	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	$1.72	-$0.05+98.1%	-$2.70-43.6%	-$1.88-347.4%	$0.76-75.6%	$3.12+229.5%	-$2.41-40.9%	-$1.71	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	N/A	N/A	N/A	63M+0.6%	62M+9.0%	57M+15.5%	50M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$28.5M	$9.9M	N/A	N/A	$0	$0	N/A	N/A
Cost of Revenue	$798K	$587K	N/A	N/A	$0	$0	N/A	N/A
Gross Profit	$27.7M	$9.3M	N/A	N/A	$0	$0	N/A	N/A
R&D Expenses	$13.8M-37.3%	$13.4M-44.0%	N/A	$16.0M-33.6%	$22.0M-51.5%	$23.8M-10.9%	N/A	$24.1M-24.1%
SG&A Expenses	$13.9M+34.0%	$13.4M+20.2%	N/A	$10.4M-8.2%	$10.3M-25.1%	$11.1M-9.3%	N/A	$11.3M-31.0%
Operating Income	$74K+100.2%	-$17.4M+50.2%	N/A	-$26.4M+25.5%	-$32.4M+45.3%	-$35.0M+10.4%	N/A	-$35.4M+26.5%
EBITDA	$416K+101.3%	-$17.2M+50.5%	N/A	-$26.0M+25.8%	-$31.9M+45.7%	-$34.7M+10.7%	N/A	-$35.0M+26.9%
Interest Expense	$7.6M+50466.7%	$5.9M+61.3%	N/A	-$13.4M-429.6%	$15K-99.8%	$3.7M-55.6%	N/A	$4.1M-48.8%
Income Tax	$29K	$57K	N/A	N/A	$0	$0	N/A	N/A
Net Income	$13.2M+152.0%	$56.1M+267.5%	N/A	-$30.9M+4.1%	-$25.4M+54.6%	-$33.5M+10.0%	N/A	-$32.2M+14.6%
EPS (Basic)	$0.18+141.9%	$0.78+234.5%	$1.42+358.2%	-$0.47+16.1%	-$0.43+55.7%	-$0.58+7.9%	-$0.55-266.7%	-$0.56+6.7%
EPS (Diluted)	$0.15+134.9%	$0.62	$1.42+358.2%	-$0.47+16.1%	-$0.43+55.7%	-$0.58+7.9%	-$0.55	-$0.56
Diluted Shares (Avg)	90M+53.0%	90M	N/A	N/A	59M	58M	N/A	N/A

OMER Balance Sheet

OMER quarterly balance sheet

Metric	FY2510-Q	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$325.6M+17.5%	$277.1M-26.8%	$378.3M-36.0%	$591.0M+41.0%	$419.3M+131.6%	$181.0M+32.2%	$137.0M+42.8%	$95.9M-17.5%	$116.3M+72.9%	$67.3M+37.3%	$49.0M+352.2%	$10.8M-34.5%	$16.5M-37.8%	$26.6M-1.5%	$27.0M
Current Assets	$215.7M+60.8%	$134.1M-38.4%	$217.9M-50.8%	$443.2M+78.8%	$248.0M+63.9%	$151.3M+45.8%	$103.7M+15.4%	$89.9M-17.1%	$108.4M+79.8%	$60.3M+62.2%	$37.1M+310.9%	$9.0M-39.0%	$14.8M-40.0%	$24.7M-4.8%	$25.9M
Cash & Equivalents	$9.7M+184.1%	$3.4M-52.1%	$7.1M-35.5%	$11.0M-89.1%	$100.8M+860.0%	$10.5M+240.5%	$3.1M-47.4%	$5.9M+72.7%	$3.4M+52.6%	$2.2M+62.9%	$1.4M+285.6%	$354K-74.4%	$1.4M-8.9%	$1.5M-62.0%	$4.0M
Short-Term Investments	$162.1M+86.9%	$86.7M-47.4%	$164.7M-10.4%	$183.9M+225.7%	$56.5M-54.6%	$124.5M+115.7%	$57.7M+5.6%	$54.6M	$0	$0	$0	$0	$0	$0	$0
Inventory	$0	N/A	N/A	N/A	N/A	$1.4M+18.1%	$1.1M+1203.4%	$88K-80.1%	$443K-60.7%	$1.1M+139.0%	$472K-16.9%	$568K	$0	N/A	N/A
Accounts Receivable	$0	N/A	N/A	N/A	$35.5M+840.6%	$3.8M-89.2%	$35.1M+54.8%	$22.7M+32.6%	$17.1M+43.1%	$11.9M+92.3%	$6.2M	$0	N/A	N/A	N/A
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$446.9M-2.8%	$459.7M+14.0%	$403.3M-20.2%	$505.3M+27.8%	$395.5M+31.0%	$301.8M+22.7%	$246.0M+25.4%	$196.1M+64.6%	$119.1M+13.8%	$104.7M+39.2%	$75.2M+40.6%	$53.5M+53.2%	$34.9M+5.5%	$33.1M+1.8%	$32.5M
Current Liabilities	$78.1M-1.8%	$79.5M+49.2%	$53.3M-60.9%	$136.4M+163.3%	$51.8M+41.0%	$36.7M-33.8%	$55.5M+48.5%	$37.4M+42.0%	$26.3M+63.7%	$16.1M-1.1%	$16.3M-11.3%	$18.3M+54.3%	$11.9M+42.0%	$8.4M-56.0%	$19.0M
Non-Current Liabilities	$368.8M-3.0%	$380.2M+8.6%	$349.9M-5.1%	$368.9M+7.3%	$343.7M+29.7%	$265.1M+39.1%	$190.5M+20.0%	$158.7M+71.0%	$92.8M+4.7%	$88.7M+50.3%	$59.0M+67.7%	$35.2M+52.6%	$23.0M-6.9%	$24.7M+82.6%	$13.6M
Long-Term Debt	$87.9M-46.7%	$164.9M-22.6%	$213.2M-32.4%	$315.3M+0.6%	$313.5M+32.7%	$236.3M+49.3%	$158.2M	N/A	$84.1M+5.8%	$79.5M+59.8%	$49.8M+90.5%	$26.1M+75.3%	$14.9M-25.9%	$20.1M+48.4%	$13.6M
Total Equity	-$121.2M+33.6%	-$182.6M-630.9%	-$25.0M-129.2%	$85.7M+260.3%	$23.8M+119.7%	-$120.8M-10.8%	-$109.0M-8.9%	-$100.2M-3459.2%	-$2.8M+92.5%	-$37.4M-42.7%	-$26.2M+38.5%	-$42.7M-132.0%	-$18.4M-181.5%	-$6.5M-17.6%	-$5.6M
Retained Earnings	-$913.7M-0.4%	-$910.3M-20.8%	-$753.5M-18.5%	-$635.7M+6.9%	-$683.1M+21.7%	-$872.7M-18.8%	-$734.6M-13.0%	-$650.1M-24.2%	-$523.4M-11.4%	-$469.9M-16.6%	-$403.1M-22.9%	-$328.0M-29.0%	-$254.4M-18.5%	-$214.6M-21.8%	-$176.1M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$286.8M+43.0%	$286.2M+21.7%	$325.6M+17.5%	$185.7M-40.7%	$200.6M-43.7%	$235.2M-46.2%	$277.1M-26.8%	$313.3M-36.5%
Current Assets	$185.2M+166.0%	$180.4M+87.5%	$215.7M+60.8%	$71.8M-56.5%	$69.6M-65.7%	$96.2M-65.8%	$134.1M-38.4%	$164.9M-53.1%
Cash & Equivalents	$2.0M+4.4%	$1.9M-55.3%	$9.7M+184.1%	$2.4M+57.5%	$1.9M-10.2%	$4.3M+132.7%	$3.4M-52.1%	$1.5M-95.0%
Short-Term Investments	$130.0M+384.2%	$133.4M+177.1%	$162.1M+86.9%	$33.7M-72.3%	$26.8M-82.9%	$48.1M-78.9%	$86.7M-47.4%	$121.6M-56.5%
Inventory	$842K	$183K	$0	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$11.7M	$6.7M	$0	N/A	N/A	N/A	N/A	N/A
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$338.2M-21.2%	$349.5M-22.1%	$446.9M-2.8%	$406.2M-13.1%	$429.3M-10.7%	$448.7M-11.8%	$459.7M+14.0%	$467.5M-7.8%
Current Liabilities	$95.0M+11.1%	$59.4M-28.6%	$78.1M-1.8%	$80.8M+45.2%	$85.5M+43.8%	$83.2M+40.9%	$79.5M+49.2%	$55.6M-62.2%
Non-Current Liabilities	$243.2M-29.2%	$290.1M-20.6%	$368.8M-3.0%	$325.4M-21.0%	$343.8M-18.4%	$365.5M-18.7%	$380.2M+8.6%	$411.9M+14.5%
Long-Term Debt	N/A	N/A	$87.9M-46.7%	$154.9M-6.1%	$154.9M-6.1%	$164.9M	$164.9M-22.6%	$164.9M-47.9%
Total Equity	-$51.3M+77.5%	-$63.3M+70.3%	-$121.2M+33.6%	-$220.5M-43.0%	-$228.7M-83.5%	-$213.6M-199.4%	-$182.6M-630.9%	-$154.2M-1005.0%
Retained Earnings	-$844.4M+12.9%	-$857.6M+9.1%	-$913.7M-0.4%	-$1.0B-13.8%	-$969.2M-14.5%	-$943.8M-19.4%	-$910.3M-20.8%	-$879.0M-18.1%

Not reported in any period shown, so not listed: Goodwill.

OMER Cash Flow Statement

OMER quarterly cash flow statement

Metric	TTM	FY2510-Q	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	-$68.7M	-$116.1M+22.0%	-$148.8M-299.1%	$74.7M+186.4%	-$86.5M+21.2%	-$109.7M-9.6%	-$100.1M-66.6%	-$60.1M+42.1%	-$103.7M-186.4%	-$36.2M+29.7%	-$51.5M+21.0%	-$65.2M	N/A	-$29.7M+14.1%	-$34.6M-34.6%	-$25.7M
Depreciation & Amortization	N/A	$964K+1.5%	$950K+3.3%	$920K-3.4%	$952K-31.3%	$1.4M-14.2%	$1.6M-9.7%	$1.8M+86.1%	$962K+74.6%	$551K+83.7%	$300K+43.5%	$209K-34.1%	$317K+5.0%	$302K-5.6%	$320K-26.4%	$435K
Stock-Based Compensation	N/A	$8.2M-21.9%	$10.5M-9.9%	$11.7M-17.2%	$14.1M-20.2%	$17.6M+18.1%	$14.9M+8.3%	$13.8M+17.7%	$11.7M-7.7%	$12.7M-6.6%	$13.6M+41.8%	$9.6M+7.4%	$8.9M+42.6%	$6.3M+46.0%	$4.3M+122.2%	$1.9M
Capital Expenditures	$56K	$65K-60.6%	$165K-61.3%	$426K+277.0%	$113K-59.2%	$277K-2.1%	$283K-15.3%	$334K-41.1%	$567K+62.0%	$350K+177.8%	$126K-47.5%	$240K+757.1%	$28K-86.3%	$204K-68.2%	$642K-48.3%	$1.2M
Free Cash Flow	-$68.7M	-$116.2M+22.0%	-$149.0M-300.5%	$74.3M+185.8%	-$86.6M+21.3%	-$110.0M-9.6%	-$100.4M-66.2%	-$60.4M+42.1%	-$104.3M-185.2%	-$36.6M+29.2%	-$51.6M+21.1%	-$65.4M	N/A	-$29.9M+15.0%	-$35.2M-30.8%	-$26.9M
Investing Cash Flow	$136.8M	$164.5M+100.1%	$82.2M+199.5%	$27.5M+121.5%	-$127.6M-165.9%	$193.7M+389.0%	-$67.0M-1870.9%	-$3.4M-113.5%	$25.2M+166.9%	-$37.6M-130.2%	-$16.3M+20.7%	-$20.6M-434.7%	$6.2M-22.2%	$7.9M+972.0%	-$907K-105.4%	$16.9M
Financing Cash Flow	-$68.1M	-$42.2M-167.1%	$62.9M+159.3%	-$106.1M-185.4%	$124.2M+1866.3%	$6.3M-96.4%	$174.5M+187.5%	$60.7M-25.1%	$81.1M+8.1%	$75.0M+9.2%	$68.7M-20.9%	$86.8M+70.7%	$50.9M+134.9%	$21.6M-34.3%	$33.0M+247.6%	$9.5M
Share Buybacks	$9.9M	$0-100.0%	$11.9M+154.6%	$4.7M	$0	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	$4.1M+118.9%	-$14.5M+59.5%	-$39.8M-37.5%	-$18.5M+42.4%	-$21.9M+52.3%	-$35.8M+14.2%	-$29.0M+16.8%	-$32.1M+1.8%
Depreciation & Amortization	$342K-21.2%	$239K-17.3%	$235K-21.9%	$386K+3.5%	$434K+24.4%	$289K+41.7%	$301K+46.8%	$373K+86.5%
Stock-Based Compensation	$1.6M-21.5%	$1.9M-23.0%	N/A	N/A	$2.1M-25.4%	$2.5M-7.7%	N/A	$2.6M-18.4%
Capital Expenditures	$45K+246.2%	$0-100.0%	$0-100.0%	$11K+1000.0%	$13K-83.8%	$41K-29.3%	$26K-78.0%	$1K-97.0%
Free Cash Flow	$4.1M+118.7%	-$14.5M+59.6%	-$39.8M-37.4%	-$18.5M+42.3%	-$22.0M+52.3%	-$35.9M+14.2%	-$29.0M+17.0%	-$32.1M+1.9%
Investing Cash Flow	$3.4M-84.0%	$28.7M-25.4%	$111.5M+219.1%	-$6.9M-119.0%	$21.3M-70.9%	$38.5M+162.2%	$35.0M-69.9%	$36.0M-37.0%
Financing Cash Flow	-$7.5M-335.1%	-$22.0M-1095.3%	-$64.4M-1473.6%	$25.8M+664.0%	-$1.7M+93.6%	-$1.8M-101.9%	-$4.1M+96.1%	-$4.6M-848.0%
Share Buybacks	$5.7M	$4.2M	$0	$0	$0	$0-100.0%	$0-100.0%	$0

Not reported in any period shown, so not listed: Dividends Paid.

OMER Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

OMER quarterly financial ratios

Metric	FY2510-Q	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	N/A	N/A	N/A	N/A	N/A	98.8%-0.4pp	99.2%+0.9pp	98.3%-0.1pp	98.3%+1.7pp	96.6%+4.3pp	92.3%-7.7pp	100.0%0.0pp	100.0%	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	-212.6%	-130.6%	-375.7%	-67.7%	-130.4%	-527.3%	N/A	-3157.3%	-612.5%	-605.9%
Net Margin	N/A	N/A	N/A	N/A	N/A	-187.0%	-75.6%	-424.4%	-82.5%	-160.4%	-555.9%	N/A	-2487.3%	-638.4%	-631.0%
Return on Equity	N/A	N/A	N/A	55.3%-761.5pp	816.8%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	N/A	N/A	N/A	8.0%-38.3pp	46.3%+122.6pp	-76.3%-14.6pp	-61.7%+70.4pp	-132.1%-86.2pp	-46.0%+53.2pp	-99.2%+54.1pp	-153.3%	N/A	-240.7%-96.0pp	-144.7%-38.9pp	-105.8%
Current Ratio	2.76+1.1x	1.69-2.4x	4.09+0.8x	3.25-1.5x	4.79+0.7x	4.12+2.2x	1.87-0.5x	2.41-1.7x	4.12+0.4x	3.75+1.5x	2.29+1.8x	0.49-0.8x	1.25-1.7x	2.95+1.6x	1.37
Debt-to-Equity	N/A	N/A	N/A	3.68-9.5x	13.18	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Asset Turnover	N/A	N/A	N/A	N/A	N/A	0.41-0.4x	0.82+0.5x	0.31-0.2x	0.56-0.1x	0.62+0.3x	0.28+0.2x	0.050.0x	0.10-0.1x	0.23+0.1x	0.17
FCF Margin	N/A	N/A	N/A	N/A	N/A	-136.0%	-54.0%	-349.2%	-56.4%	-124.1%	-484.5%	N/A	-1868.7%	-584.4%	-594.8%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	97.2%	94.1%	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	0.3%	-176.1%	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	46.4%	566.7%	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	4.6%+17.3pp	19.6%+33.8pp	N/A	-16.7%-6.4pp	-12.7%+3.0pp	-14.2%-5.7pp	N/A	-10.3%-2.6pp
Current Ratio	1.95+1.1x	3.03+1.9x	2.76+1.1x	0.89-2.1x	0.81-2.6x	1.16-3.6x	1.69-2.4x	2.96+0.6x
Asset Turnover	0.10+0.1x	0.030.0x	N/A	N/A	0.00	0.00	N/A	N/A
FCF Margin	14.4%	-146.6%	N/A	N/A	N/A	N/A	N/A	N/A

Not reported in any period shown, so not listed: Return on Equity, Debt-to-Equity.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Note: Shareholder equity is negative (-$121.2M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Omeros Corporation OMER	FY2025	N/A	N/A	N/A	$1.3B	—
Foghorn Therapeutics Inc. FHTX	FY2025	$30.9M	-$74.3M	N/A	$120.0M	48/100
Capricor Therapeutics Inc CAPR	FY2025	$0	-$105.0M	N/A	$520.3M	—
Lineage Cell Therapeutics, Inc. LCTX	FY2025	$14.6M	-$63.5M	N/A	$235.3M	59/100
Alector, Inc. ALEC	FY2025	$21.0M	-$143.0M	N/A	$202.1M	49/100
Mereo BioPharma Group plc MREO	FY2025	$500K	$41.9M	N/A	$60.7M	—

Where Omeros Corporation Ranks

Frequently Asked Questions

What is Omeros Corporation's EBITDA?

Omeros Corporation (OMER) had EBITDA of -$121.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Omeros Corporation have?

As of fiscal year 2025, Omeros Corporation (OMER) had $9.7M in cash and equivalents against $87.9M in long-term debt.

What is Omeros Corporation's free cash flow?

Omeros Corporation (OMER) recorded an outflow of $116.2M in free cash flow during fiscal year 2025. This represents a 22.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Omeros Corporation's operating cash flow?

Omeros Corporation (OMER) recorded an outflow of $116.1M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Omeros Corporation's total assets?

Omeros Corporation (OMER) had $325.6M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Omeros Corporation's capital expenditures?

Omeros Corporation (OMER) invested $65K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Omeros Corporation spend on research and development?

Omeros Corporation (OMER) invested $81.3M in research and development during fiscal year 2025.

How many shares does Omeros Corporation have outstanding?

Omeros Corporation (OMER) had 72M shares outstanding as of fiscal year 2025.

What is Omeros Corporation's current ratio?

Omeros Corporation (OMER) had a current ratio of 2.76 as of fiscal year 2025, which is generally considered healthy.

What is Omeros Corporation's P/E ratio?

Omeros Corporation (OMER) has no price-to-earnings ratio at the moment: no net income reported. The market capitalization is $1.3B as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Omeros Corporation's price-to-sales ratio?

Omeros Corporation (OMER) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $1.3B as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Omeros Corporation's liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Omeros Corporation (OMER) held $171.8M in cash, cash equivalents and investments, and reported an operating cash outflow of $116.1M over that year. Dividing the one by the other, the reported balance equals about 18 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Why is Omeros Corporation's debt-to-equity ratio negative or not reported?

Omeros Corporation (OMER) has negative shareholder equity of -$121.2M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

Can Omeros Corporation cover its interest payments?

Omeros Corporation (OMER) reported an operating loss of $122.8M against $960K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.